TVTX: FSGS Approval And 90 Day Catalyst Window Will Reshape Expectations

The analyst price target for Travere Therapeutics has shifted from $49.57 to $53.57, with analysts citing recent target increases across several firms and updated assumptions around profitability and P/E expectations as key drivers of the revision.

Analyst Commentary

Bullish and bearish analysts are looking at the same data for Travere Therapeutics and reaching different conclusions on how much value is already reflected in the stock and how much execution risk still sits ahead.

Bullish Takeaways

Bullish analysts have been lifting price targets by amounts ranging from US$2 to US$12, reflecting increased confidence in the company’s ability to reach profitability in line with updated P/E assumptions.
Several firms have raised targets more than once over the period. This suggests that incoming information around approvals and the existing pipeline is being interpreted as supportive for longer term growth potential.
An upgrade to a more positive rating after FSGS approval signals that some analysts see a clearer path to revenue scaling, which feeds directly into their valuation frameworks.
The introduction of a 90 day catalyst watch highlights that bullish analysts expect key events in the near term that could remove some uncertainty around execution and support their higher target range.

Bearish Takeaways

JPMorgan cutting its price target by US$3 shows that not all analysts are aligned with the more optimistic view, and that some see current valuation as already reflecting a generous outlook for profitability and P/E.
More cautious analysts appear focused on execution risk around delivering against expectations embedded in the recent target hikes, especially after regulatory milestones such as FSGS approval.
The mix of target increases alongside at least one target reduction suggests that opinion is split on how sustainable any perceived growth trajectory might be. This can lead to a wider range of fair value estimates.
For readers, the presence of both upward and downward target revisions is a reminder to stress test personal assumptions on timelines, revenue potential, and capital needs rather than relying on any single analyst view.

What's in the News

FDA approves FILSPARI (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, adding a second rare kidney disease indication alongside IgA nephropathy (IgAN) (Key Developments).
FILSPARI is described as the first and only FDA approved medicine for FSGS and is currently the most commonly prescribed FDA approved medicine for IgAN. Travere estimates more than 30,000 addressable FSGS patients in the U.S. who do not have nephrotic syndrome and more than 100,000 total patients across indications (Key Developments).
Phase 3 DUPLEX Study in FSGS reports a 46% reduction in proteinuria from baseline to Week 108 for FILSPARI versus 30% for maximum labeled dose irbesartan in the overall study population. The study reports a 48% versus 27% reduction in patients without nephrotic syndrome, and a reported benefit in eGFR, while maintaining a safety profile described as comparable to irbesartan (Key Developments).
FDA approval comes with a FILSPARI REMS program due to the risk of hepatotoxicity. The program requires enrollment of prescribers, patients, and pharmacies and regular monitoring of liver enzymes and bilirubin. The labeling includes pregnancy contraindications and guidance on contraception (Key Developments).
Travere highlights the Travere TotalCare support program, which offers help with understanding FSGS, prescriptions and refills, insurance processes, financial support resources, advocacy connections, and liver monitoring requirements tied to FILSPARI use (Key Developments).

Valuation Changes

Fair Value: revised from $49.57 to $53.57, a modest uplift in the modeled central estimate.
Discount Rate: adjusted slightly lower from 7.29% to 7.24%, which increases the weight placed on future cash flows in the model.
Revenue Growth: tweaked from 33.27% to 32.48%, reflecting a marginally more conservative view on future dollar revenue expansion assumptions.
Net Profit Margin: updated from 26.46% to 30.36%, indicating a higher assumed level of future dollar earnings efficiency on each dollar of sales.
Future P/E: moved from 20.51x to 18.51x, implying a lower valuation multiple being used for the outer year earnings estimate.

2 views

Key Takeaways

FILSPARI's expanding use and recognition in rare kidney diseases positions Travere for first-mover advantage, sustained growth, and meaningful gains in underserved markets.
Strong financial discipline, increasing recurring revenue, and efficient regulatory progress provide resources for pipeline advancement and future commercial launches.
Growing reliance on one key drug amid rising competition, regulatory uncertainty, and price pressures increases revenue risk and challenges long-term financial sustainability.

Catalysts

About Travere Therapeutics

A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.What are the underlying business or industry changes driving this perspective?

Expansion of FILSPARI's label to include treatment for FSGS, a rare kidney disease with no approved therapies, positions Travere for first-mover advantage in a large, underserved market-if approved, this will create a new, high-margin revenue stream and significantly expand the company's addressable market. (Revenue growth, gross margins)
Strong momentum in FILSPARI's uptake for IgA nephropathy, with broadening prescriber base, increasing initiation earlier in patient treatment, positive real-world clinical feedback, and pending updates to guidelines and REMS requirements: all expected to support sustained and deeper market penetration, boosting recurring revenue and improving operating leverage. (Recurring revenue, operating leverage)
Increasing physician and guideline recognition of proteinuria reduction as a validated surrogate endpoint (backed by new clinical and biomarker data and global registry studies), together with advances in precision medicine and disease-modifying therapies, supports long-term adoption of Travere's drug platform and positions the company to benefit from a mainstream shift to tailored, high-need therapies. (Sustained revenue, improved net margins)
Regulatory trends remain favorable for rare disease and orphan drug development, as shown by efficient progress in sNDA reviews, label expansions, potential REMS relaxation/removal, and milestone payments for international approvals-all of which improve pathways to accelerated product approvals, faster revenue realization, and enhanced pricing power. (Revenue timing, pricing power)
Travere's strengthening financial position-driven by rapid product sales growth, increased international out-licensing revenues, significant reductions in net losses, and prudent R&D and SG&A management-sets a foundation for positive net earnings, while securing resources for continued pipeline development and future commercial launches. (Earnings, cash flow, R&D investment)

Travere Therapeutics Earnings and Revenue Growth

Travere Therapeutics Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Travere Therapeutics's revenue will grow by 32.5% annually over the next 3 years.
Analysts assume that profit margins will increase from -8.5% today to 30.4% in 3 years time.
Analysts expect earnings to reach $378.4 million (and earnings per share of $3.09) by about May 2029, up from -$45.6 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $693.3 million in earnings, and the most bearish expecting $233.2 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 18.6x on those 2029 earnings, up from -89.9x today. This future PE is greater than the current PE for the US Biotechs industry at 17.2x.
Analysts expect the number of shares outstanding to grow by 4.72% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.24%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Increasing competition in the IgA nephropathy and FSGS treatment landscapes, including new classes and direct competitors entering the endothelin receptor antagonist space, could erode FILSPARI's market share, limit pricing power, and restrict long-term revenue growth.
Heavy financial reliance on FILSPARI, with other commercialized products (e.g., THIOLA/THIOLA EC) facing anticipated generic competition and modest contributions, exposes Travere to significant revenue and earnings risk if FILSPARI encounters regulatory setbacks or fails to maintain clinical differentiation.
Large ongoing R&D and SG&A expenses-driven by investments in pipeline advancement, commercial expansion, and manufacturing scale-up-may continue to pressure net margins and cash flows, particularly if new indications or products experience delays or fail to rapidly achieve commercial success.
Global and U.S. regulatory uncertainties, such as evolving REMS requirements, potential delays to FSGS approval, and changes in FDA/CEDAR review processes, could delay market entries, increase costs, or add barriers to access, thereby impacting revenue timing and earnings visibility.
Long-term risks of increasing payer scrutiny, possible gross-to-net headwinds, and anticipated future drug price pressure-especially as rare disease drug costs draw greater public, government, and payer attention-could hinder sustainable net revenue growth and compress future margins.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $53.57 for Travere Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $60.0, and the most bearish reporting a price target of just $43.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $1.2 billion, earnings will come to $378.4 million, and it would be trading on a PE ratio of 18.6x, assuming you use a discount rate of 7.2%.
Given the current share price of $44.1, the analyst price target of $53.57 is 17.7% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Travere Therapeutics?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

TVTX: Recent Regulatory Momentum Will Drive FSGS And IgAN Market Leadership